COSMO Pharmaceuticals SA (0RGI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COSMO Pharmaceuticals SA (0RGI) has a cash flow conversion efficiency ratio of 0.002x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£900.00K ≈ $1.21 Million USD) by net assets (£466.98 Million ≈ $627.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See COSMO Pharmaceuticals SA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
COSMO Pharmaceuticals SA - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how COSMO Pharmaceuticals SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
COSMO Pharmaceuticals SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSMO Pharmaceuticals SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
0.018x |
|
IMMUNOCORE HLDGS ADS/1
F:6YG
|
-0.086x |
|
Orchid Island Capital Inc.
NYSE:ORC
|
0.035x |
|
Adaptive Plasma Technology Corp
KQ:089970
|
0.056x |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
0.025x |
|
CTS Corporation
NYSE:CTS
|
0.053x |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
0.009x |
|
Ascletis Pharma Inc
F:2VJ
|
-0.018x |
Annual Cash Flow Conversion Efficiency for COSMO Pharmaceuticals SA (2004–2024)
The table below shows the annual cash flow conversion efficiency of COSMO Pharmaceuticals SA from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see COSMO Pharmaceuticals SA (0RGI) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | £505.09 Million ≈ $678.29 Million |
£162.41 Million ≈ $218.10 Million |
0.322x | +507.52% |
| 2023-12-31 | £429.04 Million ≈ $576.16 Million |
£22.71 Million ≈ $30.49 Million |
0.053x | -25.38% |
| 2022-12-31 | £463.79 Million ≈ $622.83 Million |
£32.89 Million ≈ $44.17 Million |
0.071x | +188.34% |
| 2021-12-31 | £512.68 Million ≈ $688.48 Million |
£12.61 Million ≈ $16.94 Million |
0.025x | -24.20% |
| 2020-12-31 | £400.12 Million ≈ $537.33 Million |
£12.98 Million ≈ $17.44 Million |
0.032x | +167.80% |
| 2019-12-31 | £393.73 Million ≈ $528.75 Million |
£-18.85 Million ≈ $-25.31 Million |
-0.048x | -109.50% |
| 2018-12-31 | £444.85 Million ≈ $597.40 Million |
£-10.16 Million ≈ $-13.65 Million |
-0.023x | -7.32% |
| 2017-12-31 | £470.12 Million ≈ $631.32 Million |
£-10.01 Million ≈ $-13.44 Million |
-0.021x | -133.50% |
| 2016-12-31 | £415.56 Million ≈ $558.06 Million |
£26.41 Million ≈ $35.47 Million |
0.064x | +165.40% |
| 2015-12-31 | £403.65 Million ≈ $542.06 Million |
£-39.23 Million ≈ $-52.68 Million |
-0.097x | -122.27% |
| 2014-12-31 | £152.29 Million ≈ $204.51 Million |
£66.45 Million ≈ $89.23 Million |
0.436x | +1084.01% |
| 2013-12-31 | £220.16 Million ≈ $295.65 Million |
£8.11 Million ≈ $10.90 Million |
0.037x | -80.04% |
| 2012-12-31 | £124.60 Million ≈ $167.33 Million |
£23.00 Million ≈ $30.89 Million |
0.185x | +3.72% |
| 2011-12-31 | £63.43 Million ≈ $85.19 Million |
£11.29 Million ≈ $15.16 Million |
0.178x | +33.42% |
| 2010-12-31 | £58.37 Million ≈ $78.38 Million |
£7.79 Million ≈ $10.46 Million |
0.133x | +105.80% |
| 2009-12-31 | £59.80 Million ≈ $80.30 Million |
£3.88 Million ≈ $5.21 Million |
0.065x | +122.39% |
| 2008-12-31 | £43.24 Million ≈ $58.06 Million |
£-12.52 Million ≈ $-16.81 Million |
-0.290x | -303.62% |
| 2007-12-31 | £35.15 Million ≈ $47.20 Million |
£-2.52 Million ≈ $-3.39 Million |
-0.072x | -106.31% |
| 2006-12-31 | £5.34 Million ≈ $7.18 Million |
£6.08 Million ≈ $8.16 Million |
1.137x | -57.78% |
| 2005-12-31 | £631.00K ≈ $847.38K |
£1.70 Million ≈ $2.28 Million |
2.694x | +1008.37% |
| 2004-12-31 | £-880.00K ≈ $-1.18 Million |
£261.00K ≈ $350.50K |
-0.297x | -- |
About COSMO Pharmaceuticals SA
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more